Citadel Advisors
RNAM

Citadel Advisors’s Avidity Biosciences RNAM Stock Holding History

Citadel Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-436,900
Closed -$31.5M – 14046
2025
Q4 		$31.5M Buy
436,900
+305,900
+234% +$19.8M ﹤0.01% 1846
2025
Q3 		$5.71M Buy
131,000
+109,600
+512% +$4.43M ﹤0.01% 4126
2025
Q2 		$608K Sell
21,400
-6,200
-22% -$185K ﹤0.01% 8166
2025
Q1 		$815K Buy
27,600
+500
+2% +$15.6K ﹤0.01% 7398
2024
Q4 		$788K Buy
27,100
+7,500
+38% +$313K ﹤0.01% 7541
2024
Q3 		$900K Sell
19,600
-40,400
-67% -$1.75M ﹤0.01% 7082
2024
Q2 		$2.45M Buy
60,000
+55,900
+1,363% +$1.6M ﹤0.01% 4936
2024
Q1 		$105K Sell
4,100
-3,900
-49% -$61.1K ﹤0.01% 11300
2023
Q4 		$72.4K Buy
8,000
+6,700
+515% +$44.8K ﹤0.01% 11348
2023
Q3 		$8.29K Sell
1,300
-17,300
-93% -$149K ﹤0.01% 13202
2023
Q2 		$206K Buy
18,600
+10,300
+124% +$129K ﹤0.01% 9820
2023
Q1 		$127K Sell
8,300
-28,700
-78% -$631K ﹤0.01% 10898
2022
Q4 		$821K Buy
+37,000
New +$552K ﹤0.01% 7189

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Citadel Advisors's RNAM Position: Q1 2026 in Review

Citadel Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,592,429 shares — an estimated $115M sold.

Citadel Advisors first reported a position in RNAM in Q2 2020 and held it in 16 quarters. The position peaked at $115M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Citadel Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,592,429 Avidity Biosciences shares in Q1 2026, an estimated $115M.
  • Citadel Advisors first reported a position in Avidity Biosciences in Q2 2020 and held it in 16 quarters.
  • Citadel Advisors's Avidity Biosciences position peaked at $115M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.